Focused – Innovative – Effective: We are Lorus

• Home
• About Lorus
  • Overview
  • Message from the CEO
  • Management Team
  • Board of Directors
• Products & Technology
  • Product Pipeline
  • Virulizin
  • LOR-2040
  • LOR-1284
  • LOR-253, LOR-264 and LOR-220
  • IL-17E
• Investors
  • Overview
  • Financial Reports
  • Corporate Documents
  • Stock Information
  • Conference Calls & Webcasts
  • Corporate Governance
  • FAQ
  • Investors Contact & Information Request
• News & Events
  • Press Releases
  • French Press Releases
  • Events
  • Subscription
• Business Development

• Contact
• Careers
• Subscription
• Site Map

• Product Pipeline
• Virulizin
• LOR-2040
• LOR-1284
• LOR-253, LOR-264 and LOR-220
• IL-17E

IL-17E

Interleukin-17E (IL-17E) is a protein-based therapeutic that Lorus is developing as an immunotherapy for cancer treatment. This drug candidate is derived from the cytokine IL-17E, which is a protein that is produced by cells of the immune system. Lorus' scientists were the first to discover that IL-17E has anticancer activity against a range of human cancers. Preliminary studies have revealed that IL-17E has strong in vivo efficacy against several human tumor types, including colon cancer, melanoma, and pancreatic cancer, with low toxicity. Additional preclinical studies are being done with IL-17E to further evaluate its efficacy and toxicity profile in comparison to other cytokines that are approved for cancer therapy, including interferon alpha and interleukin-2.

We are confident that IL-17E has the potential to advance towards late preclinical development, and we are currently planning further nonclinical studies to assess toxicity and optimize the therapeutic dose.